59
Participants
Start Date
March 5, 2012
Primary Completion Date
October 7, 2019
Study Completion Date
July 21, 2025
FdCyd + THU
Intravenous FdCyd with THU has been evaluated in a Phase I clinical trial with some preliminary evidence of activity. This trial will investigate oral administration of the drugs, which was shown to be feasible in an expansion cohort of the previous trial.
University of Pittsburgh Cancer Institute, Pittsburgh
Penn State, Hershey
National Institutes of Health Clinical Center, Bethesda
USC Norris Cancer Center, Los Angeles
City of Hope, Duarte
UC Davis Cancer Center, Sacramento
National Cancer Institute (NCI)
NIH